Patents by Inventor Xiaoyong Le

Xiaoyong Le has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10647694
    Abstract: A diphenylaminopyrimidine and triazine compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, hydrate or solvate thereof is disclosed In formula I, A is C or N; X and Y are independently selected from hydrogen, halo, cyano, trifluoromethyl, alkoxy, alkyl, aryl, alkenyl, alkynyl and nitro; or X and Y, together with the atoms to which they are attached, form a phenyl or an heteroaromatic ring; R1 is R2 is CD3 or CD2CD3; R3 is R4 is hydrogen, methyl, trifluoromethyl, cyano or halo; R5 is hydrogen, alkyl, substituted and unsubstituted phenyl, allyl or propargyl; R6 and R7 are independently selected from hydrogen, alkyl, substituted and unsubstituted phenyl, allyl and propargyl; or R6 and R7, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocycloalkyl group. The compound has pharmacodynamic and pharmacokinetic properties and ALK kinase inhibitory activity.
    Type: Grant
    Filed: May 4, 2017
    Date of Patent: May 12, 2020
    Assignee: ARROMAX PHARMATECH CO., LTD.
    Inventors: Jian Hong, Guobin Liu, Jingbing Wang, Xiaoyong Le
  • Publication number: 20190256493
    Abstract: A diphenylaminopyrimidine and triazine compound of Formula I, or a pharmaceutically acceptable salt, stereoisomer, hydrate or solvate thereof is disclosed In formula I, A is C or N; X and Y are independently selected from hydrogen, halo, cyano, trifluoromethyl, alkoxy, alkyl, aryl, alkenyl, alkynyl and nitro; or X and Y, together with the atoms to which they are attached, form a phenyl or an heteroaromatic ring; R1 is R2 is CD3 or CD2CD3; R3 is R4 is hydrogen, methyl, trifluoromethyl, cyano or halo; R5 is hydrogen, alkyl, substituted and unsubstituted phenyl, allyl or propargyl; R6 and R7 are independently selected from hydrogen, alkyl, substituted and unsubstituted phenyl, allyl and propargyl; or R6 and R7, together with the nitrogen atom to which they are attached, form a substituted or unsubstituted heterocycloalkyl group. The compound has pharmacodynamic and pharmacokinetic properties and ALK kinase inhibitory activity.
    Type: Application
    Filed: May 4, 2017
    Publication date: August 22, 2019
    Inventors: Jian HONG, Guobin LIU, Jingbing WANG, Xiaoyong LE
  • Patent number: 10196365
    Abstract: Disclosed are a quinazoline derivative, a preparation method therefor, and a pharmaceutical composition and an application thereof. The present invention provides a compound represented by general formula I, a stereoisomer thereof and a pharmaceutical acceptable salt or a solvate thereof. The quinazoline derivative of the present invention has a unique chemical structure, is characterized by irreversibly inhibiting EGFR tyrosine kinase, has high biological activity, apparently improves the inhibiting effect on the EGFR tyrosine kinase, has quite strong tumor inhibiting effect on tumor cells and a transplantation tumor pathological model of animal tumors, and has good market developing prospects.
    Type: Grant
    Filed: August 15, 2014
    Date of Patent: February 5, 2019
    Assignee: ARROMAX PHARMATECH CO., LTD.
    Inventors: Jian Hong, Xin Xu, Xiaoyong Le, Zonghua Zhang
  • Publication number: 20170247339
    Abstract: Disclosed are a quinazoline derivative, a preparation method therefor, and a pharmaceutical composition and an application thereof. The present invention provides a compound represented by general formula I, a stereoisomer thereof and a pharmaceutical acceptable salt or a solvate thereof. The quinazoline derivative of the present invention has a unique chemical structure, is characterized by irreversibly inhibiting EGFR tyrosine kinase, has high biological activity, apparently improves the inhibiting effect on the EGFR tyrosine kinase, has quite strong tumor inhibiting effect on tumor cells and a transplantation tumor pathological model of animal tumors, and has good market developing prospects.
    Type: Application
    Filed: August 15, 2014
    Publication date: August 31, 2017
    Inventors: Jian HONG, Xin XU, Xiaoyong LE, Zonghua ZHANG
  • Patent number: 9249172
    Abstract: Disclosed are pyrazole compounds of general formula (I), wherein R, R1, Rc, Rd, Re, Rf, X, Y, Z, A and B are as defined in the application. These compounds are active as inhibitors of poly(ADP-ribose)polymerase (PARP) and are useful in methods for treating diseases or conditions mediated by PARP, including breast cancer and malignant melanoma.
    Type: Grant
    Filed: May 23, 2011
    Date of Patent: February 2, 2016
    Assignees: HANDE PHARMA LIMITED, HANDE STARLAKE BIOSCIENXE CO., LTD.
    Inventors: Chenxi Li, Weisheng Shen, Yang Fang, Xiaoyong Le
  • Publication number: 20130142757
    Abstract: Disclosed are compounds of general formula (I), wherein R, R1, Rc, Rd, Re, Rf, X, Y, Z, A and B are as defined in the application.
    Type: Application
    Filed: May 23, 2011
    Publication date: June 6, 2013
    Applicants: Hande Starlake Bioscience Co., Ltd., Hande Pharma Limited
    Inventors: Chenxi LI, Weisheng Shen, Yang Fang, Xiaoyong Le